Trastuzumab was recently studied in the Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer Trial (APHINITY TRIAL), which sought to assess its efficacy. Here, ERBB2 is linked to breast carcinoma.